SRPT Q2 2023 Earnings — Sarepta Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SRPTSarepta Therapeutics, Inc.

$2B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$261M+11.9% YoY

Gross Profit

$227M86.9% margin

Operating Income

-$134M-51.1% margin

Net Income

-$24M-9.2% margin

EPS (Diluted)

$-0.27

QoQ Revenue Growth

+3.1%

Cash Flow

Operating Cash Flow

-$122M

Free Cash Flow

-$140M

Stock-Based Comp.

$47M

Balance Sheet

Total Assets

$3.1B

Total Liabilities

$2.4B

Stockholders' Equity

$741M

Cash & Equivalents

$852M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$261M	$233M	+11.9%
Gross Profit	$227M	$196M	+16.1%
Operating Income	-$134M	-$211M	+36.8%
Net Income	-$24M	-$231M	+89.7%

Geographic Segments

UNITED STATES

$204M85%

Non-US

$35M15%